Welcome to our dedicated page for Livongo Health news (Ticker: LVGO), a resource for investors and traders seeking the latest updates and insights on Livongo Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Livongo Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Livongo Health's position in the market.
Mendaera, a Silicon Valley-based healthcare technology company, has secured $73 million in Series B funding led by Threshold Ventures. The company is developing a handheld robotic interventional platform to address healthcare provider shortages and rising costs in mainstream medical procedures.
Mendaera's platform combines robotics, AI, real-time imaging, and virtual connectivity to improve quality and workforce productivity in common procedures like biopsies, organ and vascular access, and pain management interventions. The funding will be used to complete development of the robotic technology, accelerate AI and connectivity capabilities, and begin clinical introduction.
The company aims to enhance patient experience, increase access to high-quality care, reduce overall costs, and improve healthcare provider satisfaction by making advanced technologies more accessible across specialties and sites of service.
Salvo Health has launched a virtual health clinic aimed at addressing chronic gut conditions for over 60 million Americans. The company recently secured $10.5 million in seed funding led by Threshold Ventures, along with Torch Capital and Felicis. Salvo Health offers a comprehensive care model, Whole Self Science, that integrates various health disciplines to provide personalized treatment plans. Their approach includes unlimited access to a dedicated care team, emphasizing root cause treatment over conventional methods. The company plans to expand its services across the U.S.
Livongo Health announced a strong performance in its third quarter 2020, reporting a total revenue of $106.1 million, marking a 126% year-over-year increase. The company has over 442,000 enrolled members for its diabetes program, a rise of 113% year-over-year. Livongo achieved a GAAP gross margin of 75.6% and a non-GAAP net income of $19.2 million, translating to $0.16 per share. The Estimated Value of Agreements (EVA) reached $145.9 million, a 71% increase from the previous year. The company is optimistic about future growth, bolstered by its merger with Teladoc Health.
On October 16, 2020, GuideWell Mutual Holding Corporation announced a strategic partnership with Livongo (Nasdaq: LVGO) to enhance care for members with chronic conditions, specifically diabetes. Florida Blue, a GuideWell subsidiary, will provide access to Livongo's diabetes management platform through the Onlife Health consumer engagement solution. This collaboration aims to offer a comprehensive virtual care experience by integrating Teladoc's virtual care services with Livongo’s data capabilities. Livongo currently serves over 1,300 clients, including major corporations and health plans.
Livongo Health (Nasdaq: LVGO) is set to release its financial results for Q3 FY2020 on October 28, 2020, post-market close. Due to the pending merger with Teladoc Health, no conference call will accompany the announcement. Livongo focuses on empowering individuals with chronic conditions through insights and data-driven health management. Its innovative approach delivers improved clinical outcomes and a better overall experience for members.
On September 8, 2020, Livongo Health (Nasdaq: LVGO) announced upcoming presentations at investor conferences regarding their merger with Teladoc Health. Key events include the Wells Fargo Securities Healthcare Conference on September 10 at 8:00 a.m. ET and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16 at 9:30 a.m. ET. Livongo focuses on empowering individuals with chronic conditions through its AI-driven health solutions, improving health outcomes and experiences. Archives of the webcasts will be available on Livongo's Investor Relations site.
Livongo Health (Nasdaq: LVGO) announced that its executives will present at the KeyBanc Capital Markets Future of Technology Series on August 27, 2020, at 10:00 a.m. ET. The presentation will be available via a live webcast and archived recordings on the company's Investor Relations webpage. Livongo is focused on empowering individuals with chronic conditions, utilizing its AI-driven platform to deliver actionable health insights. The company aims to enhance clinical and financial outcomes through personalized health signals.
Livongo Health, a leader in Applied Health Signals, announced its executives will present at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 8:30 a.m. ET. The conference will feature discussions on empowering individuals with chronic conditions such as diabetes and hypertension. A live webcast of the presentation will be accessible on the company's Investor Relations website. Livongo uses advanced AI to provide personalized health insights, aiming to improve clinical and financial outcomes for its members.
Livongo Health, Inc. (NASDAQ: LVGO) reported significant growth in its second quarter of 2020, with total revenue reaching $91.9 million, a 125% increase year-over-year. The company enrolled over 410,000 Livongo for Diabetes members, reflecting a 113% rise. The GAAP net loss was $1.6 million, translating to a loss per share of ($0.02). Non-GAAP net income stood at $12.5 million, or $0.11 per diluted share. Livongo's estimated value of agreements grew to $108.7 million, up 46% year-over-year, showcasing its strong market position.
Livongo Health (Nasdaq: LVGO) has revised its revenue forecast for Q2 2020 to between $86 million to $87 million, surpassing the previous estimate of <$b>73 million to $75 million. The increase includes approximately $2 million to $3 million of non-recurring items. CEO Zane Burke stated that the growth reflects the demand for Livongo's solutions, particularly during the COVID-19 pandemic, which enhances their appeal to major employers and health plans. The company will discuss these results further on a conference call scheduled for August 6, 2020.
